The estimated Net Worth of Matthew E. Monaghan is at least $8.38 Milion dollars as of 31 May 2022. Mr. Monaghan owns over 200 units of Invacare stock worth over $13,053 and over the last 10 years he sold IVC stock worth over $29,939. In addition, he makes $8,340,920 as Chairman of the Board, President a Chief Executive Officer at Invacare.
Matthew has made over 8 trades of the Invacare stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 200 units of IVC stock worth $14,870 on 31 May 2022.
The largest trade he's ever made was buying 33,000 units of Invacare stock on 11 March 2022 worth over $49,170. On average, Matthew trades about 2,087 units every 63 days since 2015. As of 31 May 2022 he still owns at least 19,777 units of Invacare stock.
You can see the complete history of Mr. Monaghan stock trades at the bottom of the page.
Matthew E. Monaghan serves as Chairman of the Board, President, Chief Executive Officer of the Company. Prior to joining Invacare, Mr. Monaghan served as a business unit leader at Zimmer Holdings (now Zimmer Biomet NYSE: ZBH), a major orthopedic implant company, serving first as Vice President and General Manager of the company’s Global Hips business (December 2009 to January 2014) and later as Senior Vice President of Hips and Reconstructive Research (January 2014 until joining Invacare). While at Zimmer, Mr. Monaghan was responsible for the Hip Division’s new product development, engineering, marketing, clinical studies, quality, regulatory affairs and results of the shared sales and supply chain functions. Later, those responsibilities also included directing research for various areas of material, process and product innovation. Prior to joining Zimmer in 2009, Mr. Monaghan spent eight years as an operating executive for two leading private equity firms, Texas Pacific Group (TPG) and Cerberus Capital Management, where he led acquisitions and operational improvements of portfolio companies in medical device and consumer goods and service industries. For the first 13 years of his career, Mr. Monaghan held various engineering, financial and management positions at General Electric (NYSE: GE). Since November 2016, Mr. Monaghan has served as a Director of Syneos Health (NASDAQ: SYNH), a contract research organization serving the needs of pharmaceutical clients.
As the Chairman of the Board, President a Chief Executive Officer of Invacare, the total compensation of Matthew Monaghan at Invacare is $8,340,920. There are no executives at Invacare getting paid more.
Matthew Monaghan is 52, he's been the Chairman of the Board, President a Chief Executive Officer of Invacare since 2015. There are 14 older and 2 younger executives at Invacare. The oldest executive at Invacare Corp. is Susan Alexander, 63, who is the Independent Director.
Matthew's mailing address filed with the SEC is C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE, NC, 27560.
Over the last 21 years, insiders at Invacare have traded over $3,551,958 worth of Invacare stock and bought 391,450 units worth $2,325,949 . The most active insiders traders include Edward F Crawford, Aaron Malachi Iii Mixon a Steven H Azurite Management.... On average, Invacare executives and independent directors trade stock every 52 days with the average trade being worth of $10,700. The most recent stock trade was executed by Steven H Azurite Management... on 17 November 2022, trading 122,820 units of IVC stock currently worth $47,900.
Invacare Corporation is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings. At its core, the Company designs, manufactures, and distributes medical devices that help people to move, breathe, rest and perform essential hygiene. The Company provides clinically complex medical device solutions for congenital (e.g., cerebral palsy, muscular dystrophy, spina bifida), acquired (e.g., stroke, spinal cord injury, traumatic brain injury, post-acute recovery, pressure ulcers) and degenerative (e.g., ALS, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly, bariatric) ailments. The Company's products are important parts of care for people with a wide range of challenges, from those who are active and involved in work or school each day and may need additional mobility or respiratory support, to those who are cared for in residential care settings, at home and in rehabilitation centers. The Company sells its products principally to home medical equipment providers with retail and e-commerce channels, residential care operators, distributors and government health services in North America, Europe and Asia Pacific.
Invacare executives and other stock owners filed with the SEC include: